EDG-7500 – Designed to Address the Molecular Basis of Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator intended for the treatment of HCM and other diseases of cardiac diastolic dysfunction. The compound is designed to slow early contraction velocity and improve impaired cardiac relaxation. This novel mechanism is anticipated to have a broad therapeutic index that may facilitate fixed patient dosing and minimize monitoring during therapy. Preclinical data of EDG-7500 support beneficial activity in animal models of both obstructive HCM and cardiac diastolic dysfunction with minimal changes in left ventricular systolic performance.
Edgewise is currently investigating EDG-7500 in a Phase 1 clinical study in healthy volunteers. The Company is also planning future studies of EDG-7500 in individuals with obstructive HCM and other diseases of diastolic dysfunction. For more information on our clinical trials, click HERE.